Dr. Amina Zoubeidi leads identification of gene linked to growth of aggressive neuroendocrine prostate cancer (NEPC)

30/01/17

NEPC is a highly aggressive cancer that sometimes emerges in prostate cancer patients undergoing androgen deprivation therapy (ADT). Unfortunately ADT, which is common treatment for prostate cancer, had led to a correlating increase in cases of an aggressive variant called treatment-induced NEPC.
Dr. Zoubeidi’s discovery of the protein driving the emergence of NEPC is a timely and important one. It allowed her and her team to use the new genome editing CRISPR technology to turn off the gene producing that protein. They discovered that when it was turned off, the emergence of NEPC was prevented. Her work was published Cancer Discovery.

News